APA (7th ed.) Citation

Perez-Garcia, J. M., Gebhart, G., Borrego, M. R., Schmid, P., Marmé, F., Prat, A., . . . Llombart-Cussac, A. (2022). Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: A plain language summary of the PHERGain study. Future oncology, 18(33), . https://doi.org/10.2217/fon-2022-0663

Chicago Style (17th ed.) Citation

Perez-Garcia, Jose Manuel, et al. "Trastuzumab and Pertuzumab Without Chemotherapy in Early-stage HER2+ Breast Cancer: A plain Language Summary of the PHERGain Study." Future Oncology 18, no. 33 (2022). https://doi.org/10.2217/fon-2022-0663.

MLA (9th ed.) Citation

Perez-Garcia, Jose Manuel, et al. "Trastuzumab and Pertuzumab Without Chemotherapy in Early-stage HER2+ Breast Cancer: A plain Language Summary of the PHERGain Study." Future Oncology, vol. 18, no. 33, 2022, https://doi.org/10.2217/fon-2022-0663.